

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KUBO *et al.*

Appl. No. 09/017,524

Filed: February 3, 1998

For: **HLA Binding Peptides and Their
Uses**

Confirmation No. 8468

Art Unit: 1644

Examiner: DeCloux, A.M.

Atty. Docket: 2060.005000B/HCC/PAC

Fourth Supplemental Information Disclosure Statement

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

AUG 26 2003

TECH CENTER 1600/2900

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Fourth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants Third Supplemental Information Disclosure Statement filed on February 7, 2003 in connection with the above-captioned application. A copy of each document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.


Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Reg #
36,688

Date: 8/22/03

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600



FORM PTO-1449

FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
2060.005000B/HCC/PACAPPLICATION NO.
09/017,524APPLICANT
KUBO et al.FILING DATE
February 3, 1998GROUP
1644

RECEIVED

AUG 26 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG1	5,756,666	05/26/1998	Takiguchi et al.			10/19/1994
	AH1	5,763,158	06/09/1998	Bohannon			02/06/1997
	AI1	5,837,249	11/17/1998	Heber-Katz et al.			10/20/1993
	AJ1	5,932,224	08/03/1999	Chisari			06/06/1995
	AK1	6,001,349	12/14/1999	Panicali et al.			02/22/1995

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM2	WO 97/34617 A1	09/25/1997	WIPO			Yes No
	AN2	WO 99/45954 A1	09/16/1999	WIPO			Yes No
	AO2	WO 99/58658 A2	11/18/1999	WIPO			Yes No
	AP2	EP 0 427 347 A1	05/15/1991	Europe			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>17</u>	Cowan, E.P., et al., "Site-directed mutagenesis of an HLA-A3 gene identifies amino acid 152 as crucial for major histocompatibility complex-restricted and alloreactive cytotoxic T-lymphocyte recognition," <i>Proc. Natl. Acad. Sci. USA</i> 84:5014-5018, National Academy of Sciences (1987)
	AS	<u>17</u>	Culmann, B., et al., "Six epitopes reacting with human cytotoxic CD8 ⁺ T cells in the central region of the HIV-1 nef protein," <i>J. Immunol.</i> 145:1560-1565, The American Association of Immunologists (March 1991)
	AT	<u>17</u>	Sweetser, M.T., et al., "Class I Major Histocompatibility Complex-restricted T Lymphocyte Recognition of the Influenza Hemagglutinin. Overlap between Class I Cytotoxic T Lymphocytes and Antibody Sites," <i>J. Exp. Med.</i> 170:1357-1368, The Rockefeller University Press (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.